Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04799249 |
Recruitment Status :
Active, not recruiting
First Posted : March 16, 2021
Last Update Posted : January 16, 2024
|
Sponsor:
G1 Therapeutics, Inc.
Information provided by (Responsible Party):
G1 Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | June 30, 2024 |
Estimated Study Completion Date : | October 25, 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):